The incidence of heterogeneous vancomycin-intermediate Staphylococcus aureus correlated with increase of vancomycin MIC

Diagnostic Microbiology and Infectious Disease

Volumn 71, Issue 3, 2011, Pages 301-303

  Chen, Hongbin ^a   Liu, Yudong ^b,c   Sun, Wenjia ^b   Chen, Minjun ^a   Wang, Hui ^a,b,d  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b GRADUATE SCHOOL OF PEKING UNION MEDICAL COLLEGE   (China)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

Heterogeneous vancomycin intermediate S. aureus; MRSA; Vancomycin

Indexed keywords

CEFTOBIPROLE; LINEZOLID; OXACILLIN; TEICOPLANIN; TIGECYCLINE; VANCOMYCIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; HETEROGENOUS VANCOMYCIN INTERMEDIATE STAPHYLOCOCCUS AUREUS; INCIDENCE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS; VANCOMYCIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; HUMANS; INCIDENCE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCAL INFECTIONS; VANCOMYCIN; VANCOMYCIN RESISTANCE;

EID: 80053929294     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2011.06.010     Document Type: Article

References (7)

1. Ariza J., Pujol M., Cabo J., Pena C., Fernandez N., Linares J., Ayats J., Gudiol F. Vancomycin in surgical infections due to methicillin-resistant Staphylococcus aureus with heterogeneous resistance to vancomycin. Lancet 1999, 353:1587-1588.
2. Charles P.G., Ward P.B., Johnson P.D., Howden B.P., Grayson M.L. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin. Infect. Dis. 2004, 38:448-451.
3. Fowler V.G., Boucher H.W., Corey G.R., Abrutyn E., Karchmer A.W., Rupp M.E., Levine D.P., Chambers H.F., Tally F.P., Vigliani G.A., Cabell C.H., Link A.S., DeMeyer I., Filler S.G., Zervos M., Cook P., Parsonnet J., Bernstein J.M., Price C.S., Forrest G.N., Fätkenheuer G., Gareca M., Rehm S.J., Brodt H.R., Tice A., Cosgrove S.E. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N. Engl. J. Med. 2006, 355:653-665. S. aureus Endocarditis and Bacteremia Study Group.
4. Lodise T.P., Graves J., Evans A., Graffunder E., Helmecke M., Lomaestro B.M., Stellrecht K. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob. Agents Chemother. 2008, 52:3315-3320.
5. Moore M.R., Perdreau-Remington F., Chambers H.F. Vancomycin treatment failure associated with heterogeneous vancomycin-intermediate Staphylococcus aureus in a patient with endocarditis and in the rabbit model of endocarditis. Antimicrob. Agents Chemother. 2003, 47:1262-1266.
6. Soriano A., Marco F., Martinez J.A., Pisos E., Almela M., Dimova V.P., Alamo D., Ortega M., Lopez J., Mensa J. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin. Infect. Dis. 2008, 46:193-200.
7. Wootton M., Howe R.A., Hillman R., Walsh T.R., Bennett P.M., MacGowan A.P. A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital. J. Antimicrob. Chemother. 2001, 47:399-403.